[go: up one dir, main page]

NO982785L - Kromosom 13-koblet brystkreftmottagelighetsgen - Google Patents

Kromosom 13-koblet brystkreftmottagelighetsgen

Info

Publication number
NO982785L
NO982785L NO982785A NO982785A NO982785L NO 982785 L NO982785 L NO 982785L NO 982785 A NO982785 A NO 982785A NO 982785 A NO982785 A NO 982785A NO 982785 L NO982785 L NO 982785L
Authority
NO
Norway
Prior art keywords
breast cancer
relates
gene
human
brca2
Prior art date
Application number
NO982785A
Other languages
English (en)
Other versions
NO982785D0 (no
Inventor
Sean V Tavtigian
Alexander Kamb
Jacques Simard
Fergus Couch
Johanna M Rommens
Barbara L Weber
Original Assignee
Myriad Genetics Inc
Univ Pennsylvania
Hsc Res Dev Lp
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982785(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/639,501 external-priority patent/US5837492A/en
Application filed by Myriad Genetics Inc, Univ Pennsylvania, Hsc Res Dev Lp, Endorecherche Inc filed Critical Myriad Genetics Inc
Publication of NO982785D0 publication Critical patent/NO982785D0/no
Publication of NO982785L publication Critical patent/NO982785L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen relaterer generelt til human genetikk. Spesifikt relaterer den foreliggende oppfinnelsen til fremgangsmåter og materialer som er anvendt for å isolere og detektere et humant brystkreftdisponerende gen (BRCA2), noen mutante alleler av dette forårsaker mottagelighet for kreft, spesielt brystkreft. Mer spesifikt relaterer oppfinnelsen til arvelige mutasjoner i BRCA2-genet og deres anvendelse i diagnosen av predisposisjon for brystkreft. Pen foreliggende oppfinnelsen relaterer videre til somatiske mutasjoner i BRCA2-genet i human brystkreft og deres anvendelse i diagnosen og prognosen av human brystkreft, l tillegg relaterer oppfinnelsen til somatiske mutasjoner i BRCA2-genet i andre humane kreftformer og deres anvendelse i diagnosen og prognosen av humane kreftformer. Oppfinnelsen relaterer også til terapien av humane kreftformer som har en mutasjon i BRCA2-genet, inkludert genterapi, proteinutbyttingsterapi og proteinetterligning. Videre relaterer oppfinnelsen til søkningen etter legemidler for kreftterapi. Til slutt relaterer oppfinnelsen til undersøkelsen av BRCA2-genet for mutasjoner som er egnede for diagnostisering av predisposisjonen for brystkreft.
NO982785A 1995-12-18 1998-06-17 Kromosom 13-koblet brystkreftmottagelighetsgen NO982785L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57377995A 1995-12-18 1995-12-18
US57535995A 1995-12-20 1995-12-20
US57655995A 1995-12-21 1995-12-21
US58539196A 1996-01-11 1996-01-11
US08/639,501 US5837492A (en) 1995-12-18 1996-04-29 Chromosome 13-linked breast cancer susceptibility gene
PCT/US1996/019598 WO1997022689A1 (en) 1995-12-18 1996-12-17 Chromosome 13-linked breast cancer susceptibility gene

Publications (2)

Publication Number Publication Date
NO982785D0 NO982785D0 (no) 1998-06-17
NO982785L true NO982785L (no) 1998-08-17

Family

ID=27541925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982785A NO982785L (no) 1995-12-18 1998-06-17 Kromosom 13-koblet brystkreftmottagelighetsgen

Country Status (11)

Country Link
US (2) US6124104A (no)
EP (1) EP0785216B2 (no)
JP (1) JP3455228B2 (no)
AT (1) ATE230759T1 (no)
AU (1) AU1461597A (no)
CA (1) CA2239733C (no)
DE (1) DE69625678T3 (no)
IL (1) IL124620A0 (no)
NO (1) NO982785L (no)
NZ (1) NZ326525A (no)
WO (1) WO1997022689A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US6617104B2 (en) 1996-12-03 2003-09-09 Michael R. Swift Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
GB9708221D0 (en) * 1997-04-23 1997-06-11 Cancer Res Campaign Tech Substances and uses thereof
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
AU9292898A (en) * 1997-08-15 1999-03-08 Oncormed, Inc. Coding sequence haplotypes of the human brca2 gene
US6051379A (en) * 1997-09-23 2000-04-18 Oncormed, Inc. Cancer susceptibility mutations of BRCA2
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US7148016B1 (en) * 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
WO2002036761A2 (en) 2000-11-03 2002-05-10 Dana Farber Cancer Institute Compositions and methods for the diagnosis of cancer
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US6816789B2 (en) * 2001-04-19 2004-11-09 Varian, Inc. Method and system for analyzing chromatograms
DK1402073T3 (da) * 2001-06-05 2007-06-11 Auckland Uniservices Ltd Fremgangsmåder og præparater til vurdering af lungefunktion og -lidelser
AU2002359398A1 (en) * 2001-11-16 2003-06-10 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate brca2 and methods of use
EP1990055A3 (en) * 2001-11-29 2011-11-16 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
US8076065B2 (en) * 2005-05-19 2011-12-13 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
EP1888776A4 (en) * 2005-05-19 2009-07-29 Synergenz Bioscience Ltd METHODS AND COMPOSITIONS FOR ASSESSING FUNCTION AND PULMONARY DISORDERS
US7933722B2 (en) * 2005-05-20 2011-04-26 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
KR101356305B1 (ko) 2006-05-18 2014-01-28 몰큘라 프로파일링 인스티튜트, 아이엔씨 질병 상태에 대한 개별화된 의료 개입을 결정하기 위한 시스템 및 방법
EP2134876B1 (en) * 2006-06-22 2014-05-07 Pomorski Uniwersytet Medyczny Determining a predisposition to breast cancer by identification of genotype combinations of specific variants of the genes cyp1b1, brca2 and chek2
ES2548690T3 (es) 2006-08-11 2015-10-20 Johns Hopkins University Secuencias consenso de codificación de cánceres colorrectales humanos
US7993835B1 (en) * 2007-05-11 2011-08-09 Myriad Genetics, Inc. BRCA2 mutations and use thereof
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
BRPI0921043A2 (pt) 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings métodos e sistemas para usar exossomas para determinar fenótipos
WO2011057125A2 (en) * 2009-11-05 2011-05-12 Myriad Genetics, Inc. Compositions and methods for determining cancer susceptibility
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
CA2946289C (en) * 2014-03-25 2018-08-07 Five3 Genomics, Llc Systems and methods for rna analysis in functional confirmation of cancer mutations
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN104962613B (zh) * 2015-06-02 2019-12-03 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5773278A (en) † 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
ATE259378T1 (de) * 1995-11-23 2004-02-15 Cancer Res Campaign Tech Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen
GB2307477B (en) * 1995-11-23 1997-10-22 Cancer Res Campaign Tech Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US5879890A (en) † 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
WO1998049324A2 (en) † 1997-04-30 1998-11-05 Genzyme Limited Carbohydrate-deficient glycoprotein syndrome type i
WO1998055650A1 (en) † 1997-06-04 1998-12-10 Rijksuniversiteit Te Leiden A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6376176B1 (en) † 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
JP2003526660A (ja) † 2000-03-16 2003-09-09 スカンポ・アクチェンゲゼルシャフト 高眼圧症および緑内障の治療
AU2000243515A1 (en) † 2000-04-13 2001-10-30 Genaissance Pharmaceuticals, Inc. Association of beta2-adrenergic receptor haplotypes with drug response
WO2002100897A2 (fr) † 2001-06-13 2002-12-19 Centre National De La Recherche Scientifique (C.N.R.S.) Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques

Also Published As

Publication number Publication date
DE69625678T3 (de) 2006-11-09
NZ326525A (en) 1999-11-29
DE69625678D1 (de) 2003-02-13
EP0785216B2 (en) 2006-06-07
NO982785D0 (no) 1998-06-17
CA2239733C (en) 2001-04-03
ATE230759T1 (de) 2003-01-15
IL124620A0 (en) 1998-12-06
WO1997022689A1 (en) 1997-06-26
AU1461597A (en) 1997-07-14
US6124104A (en) 2000-09-26
CA2239733A1 (en) 1997-06-26
DE69625678T2 (de) 2003-11-06
JP3455228B2 (ja) 2003-10-14
EP0785216B1 (en) 2003-01-08
US6033857A (en) 2000-03-07
EP0785216A1 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
NO982785D0 (no) Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (en) Chromosome 13-linked breast cancer susceptibility gene
MX9701075A (es) Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
CA2196790A1 (en) 17q-Linked Breast and Ovarian Cancer Susceptibility Gene
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
ATE346150T1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application